Crescent Biopharma (Nasdaq: CBIO) granted inducement stock options covering an aggregate 16,950 ordinary shares to two non-executive employees under its 2025 Employment Inducement Incentive Award Plan.
The options, approved May 28, 2026, have a 10-year term, a $21.47 exercise price, and time-based vesting over four years.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – CBIO
-4.50%
1 alert
-4.50%Session close to close
$564.54MMarket Cap
0.0xRel. Volume
In the Jun 1 session, CBIO declined 4.50%, reflecting a moderate negative market reaction.
This announcement details routine inducement option grants for two non‑executive hires, covering 16,...
Analysis
This announcement details routine inducement option grants for two non‑executive hires, covering 16,950 shares at an exercise price of $21.47 with a 10-year term and four‑year vesting schedule. It adds modest, service‑based equity compensation on top of Crescent’s existing capital structure. In context of recent trial progress, funding into 2028, and prior inducement grants, this filing mainly underscores ongoing team build‑out rather than signaling a change in financial or clinical outlook.
Key Figures
Inducement option shares:16,950 sharesEmployees receiving grants:2 employeesExercise price:$21.47 per share+5 more
8 metrics
Inducement option shares16,950 sharesAggregate options for two non-executive employees
Announced inducement option grants to two employees totaling 12,525 shares.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent news items, including trial updates, earnings and prior inducement grants, have generally seen positive or modestly positive 24-hour price reactions.
Recent Company History
Over the past months, Crescent Biopharma reported Q1 2026 results with cash of $189.2 million expected to fund operations into 2028, and highlighted progress in its ASCEND Phase 1/2 trial and broader oncology pipeline. It has repeatedly used equity inducement option grants for non‑executive hires, similar to today’s awards. Conference participation and an upcoming ASCO 2026 ASCEND presentation rounded out visibility efforts, with most announcements followed by positive next‑day price moves.
"shares to two non-executive employees as equity inducement awards under"
Equity inducement awards are special stock-based rewards given to new employees to encourage them to join a company or stay long-term. They are like signing bonuses paid with company shares instead of cash, helping motivate employees to contribute to the company's success.
nasdaq listing rule 5635(c)(4)regulatory
"with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
exercise pricefinancial
"a 10-year term and an exercise price equal to $21.47, the closing price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
option agreementfinancial
"terms of the Inducement Plan and the terms and conditions of an option agreement"
An option agreement is a contract that gives one party the right, but not the obligation, to buy or sell a specific asset (like company shares or property) at a pre-agreed price within a set time period. Think of it like a reservation or ticket that holds a purchase at today’s terms for later — it matters to investors because it can create potential future value or liability, change ownership stakes, and affect share dilution and company control.
WALTHAM, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the independent Compensation Committee of its Board of Directors approved the grant of options to purchase an aggregate of 16,950 shares of the Company’s ordinary shares to two non-executive employees as equity inducement awards under the Crescent Biopharma, Inc. 2025 Employment Inducement Incentive Award Plan, as amended (the “Inducement Plan”). The options were approved on May 28, 2026 and were material to each employee's acceptance of employment with Crescent, in accordance with Nasdaq Listing Rule 5635(c)(4).
The options were granted with a 10-year term and an exercise price equal to $21.47, the closing price per share of Crescent’s ordinary shares as reported by Nasdaq on May 28, 2026. The options granted to each employee shall vest and become exercisable as to one-fourth (1/4th) of the shares subject to the respective options on the first anniversary of the employee’s start date, and one-forty-eighth (1/48th) of the shares subject to the respective options shall vest and become exercisable monthly thereafter, in each case, subject to continuous service with Crescent through the applicable vesting dates. The options are subject to the terms of the Inducement Plan and the terms and conditions of an option agreement covering the applicable grant.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
What inducement stock options did Crescent Biopharma (Nasdaq: CBIO) grant on May 28, 2026?
Crescent Biopharma granted options to buy an aggregate 16,950 ordinary shares to two non-executive employees. According to Crescent Biopharma, these equity inducement awards were approved under the 2025 Employment Inducement Incentive Award Plan and were material to each employee’s acceptance of employment.
What is the exercise price and term of Crescent Biopharma (CBIO) 2026 inducement options?
The inducement options have a 10-year term and an exercise price of $21.47 per share. According to Crescent Biopharma, this price equals the May 28, 2026 Nasdaq closing price of its ordinary shares, aligning the grants with market value at approval.
How do the Crescent Biopharma (CBIO) inducement stock options vest for new employees?
The options vest 25% on the first anniversary of each employee’s start date, then monthly thereafter. According to Crescent Biopharma, one-forty-eighth of the shares vests monthly after year one, subject to continuous service through each applicable vesting date.
Why did Crescent Biopharma use Nasdaq Listing Rule 5635(c)(4) for CBIO inducement awards?
Crescent Biopharma used Nasdaq Listing Rule 5635(c)(4) to grant equity awards as a material inducement to employment. According to Crescent Biopharma, these options were important to each employee’s acceptance and were made under the company’s 2025 Employment Inducement Incentive Award Plan.
How many shares are covered by Crescent Biopharma’s May 2026 inducement option grants?
The May 2026 inducement grants cover options to purchase an aggregate 16,950 ordinary shares for two employees. According to Crescent Biopharma, these options are issued under the 2025 Employment Inducement Incentive Award Plan and are governed by individual option agreements.
